RxDoctor Payments Data

David Allen

Dermatology · Ogden, UTNPI 1487672986

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Boehringer Ingelheim at 46.8% of the total. Reporting peaked in 2023 at $3,030 and has fallen 81.5% since, to $560 in 2025.

$5,339in general payments, 2019–2025

Across 168 payments — averaging $31.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$3K
  • Novartis$858
  • AbbVie$610
  • Johnson & Johnson$250
  • Sanofi$233
  • E.r. Squibb & Sons, L.L.C.$165
  • plus $723 from 15 others

What the payments were for

  • Consulting fees$2,50047%
  • Food & beverage$2,72451%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,339 in reported general payments places this provider in the 80th percentile of 163 dermatology providers in Utah.

See all dermatology providers in Utah

Medicare billing

Part B allowed, 2024
$334,090
Medicare patients
893
Services billed
6,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab18$157,990
Dupixent PenDupilumab16$69,331
Fluorouracil129$10,559
Fluocinonide99$5,040
Clobetasol Propionate67$5,027
Triamcinolone Acetonide407$4,783
Desonide69$4,024
Clindamycin Phosphate122$3,860
Ketoconazole210$3,286
Metronidazole66$3,230
Doxycycline Hyclate19$3,180
Tacrolimus14$1,355
Econazole Nitrate38$1,271
Hydroxychloroquine Sulfate33$1,183
Halobetasol Propionate13$998

Paid to pharmacies, not to this prescriber.

Other dermatology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →